Navigation Links
Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
Date:4/30/2009

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources

WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA) market, which reached nearly $2 billion in 2008 in the United States, France, Germany, Italy, Spain and United Kingdom. These agents have revolutionized the treatment of niche immune diseases known as the seronegative SpAs - ankylosing spondylitis, psoriatic arthritis, and reactive arthritis - and ushered in a period of strong sales growth in these markets.

The new Spectrum report entitled Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases finds that the need for efficacious therapies to treat SpAs resulted in strong adoption of TNF-alpha inhibitors and, in turn, has proven to be a source of additional sales for blockbuster agents such as Enbrel, Remicade and Humira. In addition, physicians' familiarity with TNF-alpha inhibitors is expected to aid in the uptake of the newest agent in this drug class, Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe's Simponi, which was approved in late April by the Food and Drug Administration (FDA) for the treatment of psoriatic arthritis and ankylosing spondylitis.

"Simponi's advantages over existing TNF-alpha inhibitors are appealing to rheumatologists, and we forecast strong adoption for this agent," said Decision Resources Analyst Jennifer Moniz Carpenter, M.B.A. "However the success of the TNF-alpha inhibitors has reduced the level of perceived need in these markets, and in order to be successful in this space, other companies developing agents for SpAs - including Bristol-Myers Squibb, Novartis and Celgene - will need to fully understand the dynamics and remaining needs of the individual indications that it comprises."

According to the report, the SpA market will continue to grow over the next five to ten years, although the sales picture across the three diseases will vary widely as the reactive arthritis drug sector is markedly different than the sectors for the other two diseases. While the combined market in 2008 for ankylosing spondylitis and psoriatic arthritis was approximately $1.8 billion, the reactive arthritis drug market in that year was only $3 million, and TNF-alpha inhibitors have not been widely incorporated into medical practice for this exceedingly rare disease.

About Spectrum's Strategic Overviews

Spectrum's Strategic Overviews are comprehensive examinations of dynamic biopharmaceutical markets and industry issues. Primary research, data analysis, thought-leader consultation and the expertise of the industry-savvy Spectrum staff drive reports that offer breadth of coverage along with depth of strategic insight.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adoption of Consumer-Driven Health Plans Accelerated by Recession
2. Siemens Enhances Knowledge-Driven Solutions to Support Provider Quality of Care Initiatives
3. Leader in Health Plan Cost Containment Cites Three Economy-Driven Reasons Why Self-Insured Health Plans Should Brace for Claim Increases and Fund Reserves Accordingly
4. Brain Fitness Industry Growth Driven By Science
5. Star-Driven Benefit Event to Help Provide Music Therapy to Sick Children
6. Parents and Advocates Label Todays Vaccine Court Rulings Insincere and Politically Driven, Says National Autism Association
7. HealthCentral Acquires Wellsphere Creating the Largest Organically Driven Online Health and Wellness Communities
8. Onvia Fills Critical Information Gap with Launch of its Economic Stimulus Toolkit, Enabling Businesses to Understand, Prepare for and Capitalize on Pending Stimulus-Driven Opportunities
9. MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
10. Risk takers, drug abusers driven by decreased ability to process dopamine
11. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... , ... Center for Autism and Related Disorders (CARD) Portland today announced plans ... (ASD) and other developmental disabilities. The group, which is being launched with the help ... opportunity to share stories and advice, seek help, and continue their education on how ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... interview of two ostomy patients, standing as living proof that attitude and determination ... digestive diseases and issues that spike around the holidays. This campaign will offer ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... ... 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable ... wearable health technology on the market can deliver all that rejiva can. , “Rejiva ... about their health than the usual heart rate and steps taken”, adds Evens Augustin, ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, ein ... HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
Breaking Medicine Technology: